Prosecution Insights
Last updated: May 29, 2026

Mitsubishi Tanabe Pharma Corporation

13 pending office actions • 10 art units • 13 examiners • 5 of 13 (38%) have an AI response strategy ready • 8 patents granted in the last 365 days

Portfolio Summary

13
Total Pending OAs
6
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

9
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (9)Due ≤ 30 days (2)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (8%)
8
Medium (62%)
1
Easy (8%)
3
Unknown (23%)

Rejection Statute Mix

BucketCases
§101 only1 (8%)
§103 only4 (31%)
§102 only4 (31%)
§112 only1 (8%)
No statute on record3 (23%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

11
Life Sciences
85% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
15% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KENYON, JOHN S 1 80.3% +17.4%
KANAAN, LIZA TONY 1 22.4% +35.2%
SAEED, KAMAL A 1 84.1% +9.3%
CHANDRAKUMAR, NIZAL S 1 72.6% +18.2%
PORTER, RACHEL L 1 21.0% +22.4%
ANDERSON, JAMES D 1 55.1% +19.2%
CORNET, JEAN P 1 42.0% +47.8%
MOSELEY II, NELSON B 1 68.1% +41.7%
WANG, CHANG YU 1 33.6% +53.0%
SZNAIDMAN, MARCOS L 1 36.9% +15.9%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19322058 NOVEL B0AT1 INHIBITOR KENYON, JOHN S 53d

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18839045 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD AND PROGRAM KANAAN, LIZA TONY 43d overdue
18549653 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM PORTER, RACHEL L 13d

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17757955 AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA WANG, CHANG YU 49d overdue
18839045 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD AND PROGRAM KANAAN, LIZA TONY 43d overdue
17792673 AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY MOSELEY II, NELSON B 36d overdue
17772856 THERAPEUTIC METHODS USING VADADUSTAT SZNAIDMAN, MARCOS L 19d overdue
18001917 MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT ANDERSON, JAMES D 8d overdue
18009128 PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS CORNET, JEAN P 4d overdue
18549653 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM PORTER, RACHEL L 13d
19322058 NOVEL B0AT1 INHIBITOR KENYON, JOHN S 53d

Top Art Units

Art UnitApps
1625 2
1628 2
1675 2
3683 1
1626 1
3684 1
1629 1
1642 1
1623 1
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19322058 NOVEL B0AT1 INHIBITOR KENYON, JOHN S 1625 §102 Final Rejection 53d Pending Sep 08, 2025
18839045 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD AND PROGRAM KANAAN, LIZA TONY 3683 §102 Non-Final OA 43d overdue AI Ready Aug 16, 2024
18500142 METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS AND METHOD FOR SUPPRESSING PROGRESS OF AMYOTROPHIC LATERAL SCLEROSIS SAEED, KAMAL A 1626 Other Non-Final OA 97d overdue AI Ready Nov 02, 2023
18498377 OPTICALLY ACTIVE PYRROLIDINE COMPOUND AND METHOD FOR PRODUCING SAME CHANDRAKUMAR, NIZAL S 1625 §103 Non-Final OA 76d Pending Oct 31, 2023
18549653 INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM PORTER, RACHEL L 3684 §101 Final Rejection 13d AI Ready Sep 08, 2023
18001917 MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT ANDERSON, JAMES D 1629 §102 Non-Final OA 8d overdue Pending Dec 15, 2022
18009128 PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS CORNET, JEAN P 1628 Other Final Rejection 4d overdue AI Ready Dec 08, 2022
17792673 AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY MOSELEY II, NELSON B 1642 Other Final Rejection 36d overdue Pending Jul 13, 2022
17757955 AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA WANG, CHANG YU 1675 §102 Final Rejection 49d overdue Pending Jun 24, 2022
17772856 THERAPEUTIC METHODS USING VADADUSTAT SZNAIDMAN, MARCOS L 1628 §103 Final Rejection 19d overdue Pending Apr 28, 2022
17513383 PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF MCMILLIAN, KARA RENITA 1623 §103 Final Rejection 21d AI Ready Oct 28, 2021
17276106 HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION DONOGHUE, BRITTNEY ERIN 1675 §103 Non-Final OA 46d overdue Pending Mar 12, 2021
17258741 PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED PETRASH, HILARY ANN 1644 §112 Non-Final OA 125d overdue Pending Jan 07, 2021

Managing Mitsubishi Tanabe Pharma Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month